Ben Solomon is involved in practice-changing lung cancer clinical trials with novel inhibitors of ALK, ROS1, NTRK, BRAF, cMET, RET, and KRAS, including pivotal trials leading to the registration of drugs including crizotinib, ceritinib, lorlatinib, repotrectinib, and selpercatinib. He has more than 200 peer-reviewed publications and has been recognised as a Clarivate Highly Cited Researcher (2019, 2020, 2021, 2022).
Ben was elected to the International Association for the Study of Lung Cancer (IASLC) Board in 2023, and is also a Board member of the Cancer Council of Victoria.
